Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Symbotic Inc (SYM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Symbotic IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Symbotic Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Symbotic Inc trades at $41.95 (market cap $5.41B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 24.8× Symbotic Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.

SYMVRTX
Market Cap
$5.41B$134.25B
Sector
TechnologyHealth
52-Week High
$87.30$529.65
52-Week Low
$38.57$376.62
Enterprise Value
$3.67B$128.37B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Symbotic Inc

Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.

Read more on SYM

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX